$1.31
3.15% today
Nasdaq, Apr 02, 10:00 pm CET
ISIN
US83548R1059
Symbol
SONN
Sector
Industry

Sonnet BioTherapeutics Holdings Inc Stock price

$1.31
-0.20 13.25% 1M
-4.22 76.29% 6M
-0.15 10.27% YTD
-13.89 91.38% 1Y
-947.58 99.86% 3Y
-15,558.85 99.99% 5Y
-1,499,096.29 100.00% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.04 3.15%
ISIN
US83548R1059
Symbol
SONN
Sector
Industry

Key metrics

Market capitalization $3.89m
Enterprise Value $-860.00k
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.10
EV/Sales (TTM) EV/Sales -0.86
P/S ratio (TTM) P/S ratio 3.89
P/B ratio (TTM) P/B ratio 0.95
Revenue growth (TTM) Revenue growth 674.14%
Revenue (TTM) Revenue $1.00m
EBIT (operating result TTM) EBIT $-13.41m
Free Cash Flow (TTM) Free Cash Flow $-8.43m
Cash position $4.86m
EPS (TTM) EPS $-11.31
P/S forward 3.89
EV/Sales forward negative
Short interest 1.69%
Show more

Is Sonnet BioTherapeutics Holdings Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

Sonnet BioTherapeutics Holdings Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Sonnet BioTherapeutics Holdings Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Sonnet BioTherapeutics Holdings Inc:

Buy
100%

Financial data from Sonnet BioTherapeutics Holdings Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
1 1
669% 669%
100%
- Direct Costs 0.09 0.09
13% 13%
9%
0.91 0.91
1,720% 1,720%
91%
- Selling and Administrative Expenses 7.36 7.36
27% 27%
736%
- Research and Development Expense 6.88 6.88
19% 19%
688%
-13 -13
6% 6%
-1,332%
- Depreciation and Amortization 0.09 0.09
13% 13%
9%
EBIT (Operating Income) EBIT -13 -13
6% 6%
-1,341%
Net Profit -9.43 -9.43
35% 35%
-943%

In millions USD.

Don't miss a Thing! We will send you all news about Sonnet BioTherapeutics Holdings Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Sonnet BioTherapeutics Holdings Inc Stock News

Neutral
GlobeNewsWire
one day ago
PRINCETON, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeted to the tumor microenvironment (TME), today announced the release of a corporate update video. Access the video here.
Neutral
GlobeNewsWire
one day ago
PRINCETON, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing immunotherapeutic drugs targeted to the tumor microenvironment (TME), today announced with deep and profound sadness the tragic passing of Pankaj Mohan, Ph.D., Sonnet Founder and Chief Executive Officer. The Company's Board of D...
Neutral
GlobeNewsWire
7 days ago
SON-1010 is being studied as a combination therapy with trabectedin (Yondelis ® ), the first FDA-approved treatment for two types of advanced soft tissue sarcoma after failure of standard chemotherapy, due to the potential for immune mechanism synergies and enhancement of progression-free survival (PFS)
More Sonnet BioTherapeutics Holdings Inc News

Company Profile

Sonnet BioTherapeutics Holdings, Inc. engages in the development of biologic drugs with enhanced single or bispecific mechanisms. Its technology utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. The company was founded on April 1, 2020 and is headquartered in Princeton, New Jersey.

Head office United States
CEO Pankaj Mohan
Employees 13
Founded 2011
Website www.sonnetbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today